Abstract | BACKGROUND: METHODS: We retrospectively analyzed data on 10288 patients with ACS included in the OPUS-TIMI 16 trial and received aspirin and either the oral IIb/IIIa inhibitor orbofiban or placebo. RESULTS: Inhospital GI bleeding rate was significantly lower in patients who were receiving lipid-lowering drugs before admission compared with those who were not (0.2% vs 0.6%, P = .031). Throughout 10 months of follow-up, GI bleeding occurred in 1.8% of non- statin users compared with 1.0% of statin users (P = .001). Statin use was associated with less overall bleeding in both the orbofiban (1.4% vs 2.4%, P = .006) and the placebo groups (0.2% vs 0.8%, P = .047). Severe and major bleeding occurred less frequently with statin use (0.8% vs 1.5%, P = .001) in both the orbofiban (1.1% vs 2.0%, P = .006) and the placebo groups (0.1% vs 0.5%, P = .119). Logistic regression analysis showed that age > 65 years, orbofiban treatment, Killip class > 1, history of cerebrovascular disease, and calcium-channel blocker use were associated with higher risk of GI bleeding, whereas statin therapy was associated with a lower risk (odds ratio 0.68, 95% CI 0.45-1.04, P = .079). CONCLUSIONS:
Statins may exert protective effect against GI bleeding in patients with ACS. Additional studies are warranted to explore this additional potential benefit of statins.
|
Authors | Shaul Atar, Christopher P Cannon, Sabina A Murphy, Salvatore Rosanio, Barry F Uretsky, Yochai Birnbaum |
Journal | American heart journal
(Am Heart J)
Vol. 151
Issue 5
Pg. 976.e1-6
(May 2006)
ISSN: 1097-6744 [Electronic] United States |
PMID | 16644315
(Publication Type: Journal Article)
|
Chemical References |
- Anticoagulants
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Platelet Glycoprotein GPIIb-IIIa Complex
- Pyrrolidines
- orbofiban
- Alanine
- Aspirin
|
Topics |
- Acute Disease
- Administration, Oral
- Aged
- Alanine
(administration & dosage, adverse effects, therapeutic use)
- Anticoagulants
(adverse effects, therapeutic use)
- Aspirin
(adverse effects, therapeutic use)
- Coronary Disease
(drug therapy)
- Female
- Gastrointestinal Hemorrhage
(chemically induced, epidemiology, physiopathology, prevention & control)
- Hospitalization
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(therapeutic use)
- Incidence
- Male
- Middle Aged
- Patient Discharge
- Platelet Glycoprotein GPIIb-IIIa Complex
(antagonists & inhibitors)
- Pyrrolidines
(administration & dosage, adverse effects, therapeutic use)
- Retrospective Studies
- Risk Assessment
- Severity of Illness Index
- Syndrome
|